CN117030580A - LDNs在坏死性小肠结肠炎诊断中的应用 - Google Patents
LDNs在坏死性小肠结肠炎诊断中的应用 Download PDFInfo
- Publication number
- CN117030580A CN117030580A CN202311199796.3A CN202311199796A CN117030580A CN 117030580 A CN117030580 A CN 117030580A CN 202311199796 A CN202311199796 A CN 202311199796A CN 117030580 A CN117030580 A CN 117030580A
- Authority
- CN
- China
- Prior art keywords
- fluorescent
- hla
- nec
- cd11b
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000004995 necrotizing enterocolitis Diseases 0.000 title claims abstract description 49
- 206010051606 Necrotising colitis Diseases 0.000 title claims abstract description 17
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 title claims abstract description 17
- 238000003745 diagnosis Methods 0.000 title abstract description 14
- 125000003394 beta-D-GalNAc-(1->4)-beta-D-GlcNAc-yl group Chemical group C(C)(=O)N[C@H]1[C@@H](O[C@@H]([C@@H]([C@@H]1O)O)CO)O[C@H]1[C@@H]([C@H](C(O[C@@H]1CO)*)NC(C)=O)O 0.000 title abstract 2
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims abstract description 24
- 102000006354 HLA-DR Antigens Human genes 0.000 claims abstract description 24
- 108010058597 HLA-DR Antigens Proteins 0.000 claims abstract description 24
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims abstract description 24
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims abstract description 24
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims abstract description 24
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims abstract description 24
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims abstract description 24
- 102100022338 Integrin alpha-M Human genes 0.000 claims abstract description 24
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims abstract description 23
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims abstract description 23
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims abstract description 23
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 8
- 239000011886 peripheral blood Substances 0.000 claims abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 238000001514 detection method Methods 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 9
- 238000000684 flow cytometry Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 abstract description 32
- 210000004027 cell Anatomy 0.000 abstract description 21
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract description 9
- 238000013399 early diagnosis Methods 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 238000013211 curve analysis Methods 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 238000004393 prognosis Methods 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 230000004083 survival effect Effects 0.000 abstract description 3
- 239000003550 marker Substances 0.000 abstract 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 17
- 238000000034 method Methods 0.000 description 8
- 210000000440 neutrophil Anatomy 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000018773 low birth weight Diseases 0.000 description 3
- 231100000533 low birth weight Toxicity 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010022694 intestinal perforation Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 206010017982 Gastrointestinal necrosis Diseases 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022699 Intestinal stenosis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010036595 Premature delivery Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000006721 cell death pathway Effects 0.000 description 1
- 210000004395 cytoplasmic granule Anatomy 0.000 description 1
- 230000023011 digestive tract development Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000013385 food protein-induced enterocolitis syndrome Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 102000046699 human CD14 Human genes 0.000 description 1
- 102000056982 human CD33 Human genes 0.000 description 1
- 102000049018 human NCAM1 Human genes 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1486—Counting the particles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明提供了LDNs在坏死性小肠结肠炎诊断中的应用。本发明经过研究发现,与健康对照相比,NEC患儿外周血PBMCs中CD56‑HLA‑DR‑CD3‑CD33+CD11b+CD15+CD14‑细胞的比例明显上升,提示其可作为NEC诊断的标志物。进一步的ROC曲线分析结果显示,CD56‑HLA‑DR‑CD3‑CD33+CD11b+CD15+CD14‑细胞作为NEC诊断标志物时,AUC为0.8929,灵敏度为100%,特异度为71.43%,诊断价值较高。说明CD56‑HLA‑DR‑CD3‑CD33+CD11b+CD15+CD14‑细胞可作为特异性标志物用于NEC的诊断,能预示NEC的发生发展,有利于对患儿早诊断、早治疗,对提高患儿生存率和远期预后极为重要。
Description
技术领域
本发明属于分子诊断技术领域,尤其涉及LDNs在坏死性小肠结肠炎诊断中的应用。
背景技术
坏死性小肠结肠炎(necrotizing enterocolitis,NEC)是新生儿阶段常见的最严重的消化道疾病急症,10%的极低出生体重儿可出现。死亡率在这些极低出生体重儿中可高达30%。轻度的NEC可能与喂养不耐受表现相似,而重度NEC则在数小时内即可迅速出现肠坏死或肠穿孔等需外科手术的干预。然而手术后的幸存者大多数存在短肠综合征或者肠狭窄等严重并发症,甚至可出现神经生长发育迟缓。NEC发病的高危因素很多,包括极低出生体重、肠道发育不成熟、免疫低下、菌群失调及缺血缺氧等,其中最关键是早产。这些高危因素诱发肠道炎症造成NEC,产生一系列过度的炎症级联反应。
对于NEC的诊断,主要应用“Bell”分期标准,主要结合NEC患儿的全身表现、胃肠道症状及影像学检查制定的诊断标准。但该标准缺乏组织病理标准,不能排除如自发性肠穿孔、缺血性肠坏死、食物蛋白诱导的小肠结肠炎综合征以及其他类似于NEC临床表现而非NEC病理改变的肠道疾病。而早期诊断不明确,容易延误NEC的治疗,NEC病情发展迅速,形成重症NEC需行手术干预治疗,对患儿创伤较大。因此,寻找新的早期预测NEC的生物标志物尤为重要。
LDNs(Low Density Neutrophils),免疫表型为
CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-,研究者最初在SLE成人患者血液中证实LDNs的存在,其释放蛋白酶、防御素、组织蛋白酶、抗菌肽、促炎因子的能力增强。中性粒细胞除了吞噬作用和脱粒作用之外,还具有另一种抗微生物机制,即释放细胞外诱捕网(neutrophil extracellular traps,NETs)用以捕获与杀灭入侵的病原体。NETs是中性粒细胞DNA与组蛋白、细胞质内颗粒(源性)蛋白质形成的胞外网络结构,形成NETs的过程是一种细胞死亡通路。其中有报道指出SLE患者的致敏中性粒细胞形成NETs,特别是LDNs形成NETs的能力显著增强。
发明内容
基于此,本发明的目的在于提供LDNs在坏死性小肠结肠炎诊断中的应用。
为实现上述目的,本发明采用如下技术方案。
检测CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞在生物样本中含量的试剂在制备坏死性小肠结肠炎检测试剂或试剂盒中的应用。
在一些实施例中,所述坏死性小肠结肠炎为新生儿坏死性小肠结肠炎。
在一些实施例中,所述试剂为用于流式细胞术检测的试剂。
在一些实施例中,所述试剂包括针对CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞的荧光检测抗体。
在一些实施例中,所述荧光检测抗体包括不同荧光基团标记的抗CD56荧光抗体、抗HLA-DR荧光抗体、抗CD3荧光抗体、抗CD33荧光抗体、抗CD11b荧光抗体、抗CD15荧光抗体、抗CD14荧光抗体。
在一些实施例中,所述生物样本为外周血。
在一些实施例中,所述CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞在坏死性小肠结肠炎患者生物样本中的含量高于健康对照者。
本发明还提供了一种坏死性小肠结肠炎检测试剂盒,所述试剂盒包含用于检测CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞在生物样本中含量的试剂。
在一些实施例中,所述试剂为用于流式细胞术检测的试剂。
在一些实施例中,所述试剂包括不同荧光基团标记的抗CD56荧光抗体、抗HLA-DR荧光抗体、抗CD3荧光抗体、抗CD33荧光抗体、抗CD11b荧光抗体、抗CD15荧光抗体、抗CD14荧光抗体。
本发明经过研究发现,与健康对照相比,NEC患儿外周血PBMCs中CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞的比例明显上升,差异具有统计学意义,提示CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞可作为NEC诊断的标志物。进一步的ROC曲线分析结果显示,CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞作为NEC诊断标志物时,AUC为0.8929,灵敏度为100%,特异度为71.43%,诊断价值较高。说明CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞可作为特异性标志物用于NEC的诊断,能预示NEC的发生发展,有利于对患儿早诊断、早治疗,对提高患儿生存率和远期预后极为重要。
附图说明
图1为HDs和NEC组生物样本中LDNs含量的典型流式分析图。
图2为HDs和NEC组生物样本中LDNs含量的统计分析图。
图3为ROC曲线分析图。
具体实施方式
本发明下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。实施例中所用到的各种常用化学试剂,均为市售产品。
除非另有定义,本发明所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同。本发明的说明书中所使用的术语只是为了描述具体的实施例的目的,不用于限制本发明。
本发明的术语“包括”和“具有”以及它们任何变形,意图在于覆盖不排他的包含。例如包含了一系列步骤的过程、方法、装置、产品或设备没有限定于已列出的步骤或模块,而是可选地还包括没有列出的步骤,或可选地还包括对于这些过程、方法、产品或设备固有的其它步骤。
下面结合具体实施例进行说明。
实施例1
本实施例抽取临床NEC患儿和纠正胎龄匹配新生儿外周血样本,采用Ficoll-Hypaque密度梯度制备技术分离PBMCs,然后利用流式细胞分析技术从PBMCs中分辨出CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞。
共采集8例经临床确诊的新生儿NEC患儿和7例纠正胎龄匹配健康新生儿外周血样本。所述新生儿是指胎儿娩出母体并自脐带结扎起,至出生后未满28天这一段时间的婴儿。
具体实验步骤如下:
利用淋巴细胞分离液(天津灏洋)分离所有外周血样本中的单个核淋巴细胞(PBMC),操作步骤严格按照试剂盒说明书进行。将分离获得的PBMC按如下步骤进行染色:
(1)每个样本对应取1*106个PBMC加入流式管中,然后加入5ml PBS缓冲液混匀,2000rpm/min离心5min,弃上清,收集细胞沉淀;
(2)向所述细胞沉淀中加入100μL流式抗体稀释液,所述流式抗体稀释液包含人CD56抗体、人HLA-DR抗体、人CD3抗体、人CD33抗体、人CD11b抗体、人CD15抗体、人CD14抗体,按1:200的比例将全部种类的抗体加入PBS缓冲液中进行稀释,得到所述流式抗体稀释液;
(3)将流式管置于涡旋振荡器上振荡混匀,然后于4℃条件下避光染色30min;
(4)向流式管中加入预冷的PBS缓冲液,然后于2000rpm/min离心5min,弃上清;加入300μL预冷PBS缓冲液重悬细胞,然后使用流式分析仪(BD Canto II,USA)上机检测,获取数据,并用FlowJo10软件进行分析。
实验结果如下:
采用如图1所示的方法分析CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞在PBMCs中的比例。如图2所示,与健康志愿者(HDs)相比,NEC患儿外周血PBMCs中CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞的比例明显上升,差异具有统计学意义(P<0.05)。结果提示CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞是NEC患儿诊断的潜在标志物。
进一步地,ROC曲线分析结果显示,CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞在用于NEC患儿诊断时,AUC为0.8929,灵敏度为100%,特异度为71.43%,诊断价值较高,说明CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞可作为特异性标志物用于NEC的诊断,能预示NEC的发生发展,有利于对患儿早诊断、早治疗,对提高患儿生存率和远期预后极为重要。
综上所述,本发明提供了CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞在NEC诊断中的应用,有利于NEC患儿的早诊早治。
以上所述实施例的各技术特征可以进行任意的组合,为使描述简洁,未对以上实施例中的各个技术特征所有可能的组合都进行描述,然而,只要这些技术特征的组合不存在矛盾,都应当认为是本说明书记载的范围。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对本发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (10)
1.检测CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞在生物样本中含量的试剂在制备坏死性小肠结肠炎检测试剂或试剂盒中的应用。
2.如权利要求1所述的应用,其特征在于,所述坏死性小肠结肠炎为新生儿坏死性小肠结肠炎。
3.如权利要求1所述的应用,其特征在于,所述试剂为用于流式细胞术检测的试剂。
4.如权利要求3所述的应用,其特征在于,所述试剂包括针对CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞的荧光检测抗体。
5.如权利要求4所述的应用,其特征在于,所述荧光检测抗体包括不同荧光基团标记的抗CD56荧光抗体、抗HLA-DR荧光抗体、抗CD3荧光抗体、抗CD33荧光抗体、抗CD11b荧光抗体、抗CD15荧光抗体、抗CD14荧光抗体。
6.如权利要求1所述的应用,其特征在于,所述生物样本为外周血。
7.如权利要求1所述的应用,其特征在于,所述CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞在坏死性小肠结肠炎患者生物样本中的含量高于健康对照者。
8.一种坏死性小肠结肠炎检测试剂盒,其特征在于,所述试剂盒包含用于检测CD56-HLA-DR-CD3-CD33+CD11b+CD15+CD14-细胞在生物样本中含量的试剂。
9.如权利要求8所述的试剂盒,其特征在于,所述试剂为用于流式细胞术检测的试剂。
10.如权利要求9所述的试剂盒,其特征在于,所述试剂包括不同荧光基团标记的抗CD56荧光抗体、抗HLA-DR荧光抗体、抗CD3荧光抗体、抗CD33荧光抗体、抗CD11b荧光抗体、抗CD15荧光抗体、抗CD14荧光抗体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311199796.3A CN117030580A (zh) | 2023-09-15 | 2023-09-15 | LDNs在坏死性小肠结肠炎诊断中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311199796.3A CN117030580A (zh) | 2023-09-15 | 2023-09-15 | LDNs在坏死性小肠结肠炎诊断中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117030580A true CN117030580A (zh) | 2023-11-10 |
Family
ID=88643337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311199796.3A Pending CN117030580A (zh) | 2023-09-15 | 2023-09-15 | LDNs在坏死性小肠结肠炎诊断中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117030580A (zh) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077665A (en) * | 1996-05-07 | 2000-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Rapid assay for infection in neonates |
CN102308214A (zh) * | 2008-12-12 | 2012-01-04 | 贝克曼考尔特公司 | 包含未偶联的藻胆蛋白的多色流式细胞术组合物 |
US20120070461A1 (en) * | 2010-09-21 | 2012-03-22 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
CN110574120A (zh) * | 2017-02-28 | 2019-12-13 | 阿尼克萨诊断公司 | 使用流式细胞术数据的人工神经网络分析进行癌症诊断的系统和方法 |
CN112512536A (zh) * | 2018-06-12 | 2021-03-16 | 加利福尼亚大学董事会 | 基于干细胞工程化inkt细胞的现成细胞疗法 |
US20220010273A1 (en) * | 2018-11-09 | 2022-01-13 | The Wistar Institute Of Anatomy And Biology | Use of lactoferrin for generating myeloid-derived suppressor cells |
CN114636826A (zh) * | 2022-03-02 | 2022-06-17 | 广州市妇女儿童医疗中心 | Cd177+中性粒细胞在制备新生儿坏死性小肠结肠炎检测产品中的应用 |
CN114929864A (zh) * | 2019-06-12 | 2022-08-19 | 加利福尼亚大学董事会 | 工程化的现成免疫细胞及其使用方法 |
CN115327117A (zh) * | 2022-09-05 | 2022-11-11 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | 孤独症诊断标志物MDSCs及其应用 |
CN115524490A (zh) * | 2022-10-24 | 2022-12-27 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | Hla-dr+cd14+cd56+单核细胞在aa或hlh中诊断的应用 |
CN116075589A (zh) * | 2020-08-28 | 2023-05-05 | 凯瑞斯马治疗公司 | 用于纤维化和炎症的修饰的免疫细胞 |
WO2023168341A1 (en) * | 2022-03-02 | 2023-09-07 | The Regents Of The University Of California | Engineered cells and methods of use |
-
2023
- 2023-09-15 CN CN202311199796.3A patent/CN117030580A/zh active Pending
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077665A (en) * | 1996-05-07 | 2000-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Rapid assay for infection in neonates |
CN102308214A (zh) * | 2008-12-12 | 2012-01-04 | 贝克曼考尔特公司 | 包含未偶联的藻胆蛋白的多色流式细胞术组合物 |
US20120070461A1 (en) * | 2010-09-21 | 2012-03-22 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
CN103180739A (zh) * | 2010-09-21 | 2013-06-26 | 伊玛提克斯生物技术有限公司 | 利用骨髓细胞生物标记诊断癌症 |
CN110574120A (zh) * | 2017-02-28 | 2019-12-13 | 阿尼克萨诊断公司 | 使用流式细胞术数据的人工神经网络分析进行癌症诊断的系统和方法 |
CN112512536A (zh) * | 2018-06-12 | 2021-03-16 | 加利福尼亚大学董事会 | 基于干细胞工程化inkt细胞的现成细胞疗法 |
US20220010273A1 (en) * | 2018-11-09 | 2022-01-13 | The Wistar Institute Of Anatomy And Biology | Use of lactoferrin for generating myeloid-derived suppressor cells |
CN114929864A (zh) * | 2019-06-12 | 2022-08-19 | 加利福尼亚大学董事会 | 工程化的现成免疫细胞及其使用方法 |
CN116075589A (zh) * | 2020-08-28 | 2023-05-05 | 凯瑞斯马治疗公司 | 用于纤维化和炎症的修饰的免疫细胞 |
CN114636826A (zh) * | 2022-03-02 | 2022-06-17 | 广州市妇女儿童医疗中心 | Cd177+中性粒细胞在制备新生儿坏死性小肠结肠炎检测产品中的应用 |
WO2023168341A1 (en) * | 2022-03-02 | 2023-09-07 | The Regents Of The University Of California | Engineered cells and methods of use |
CN115327117A (zh) * | 2022-09-05 | 2022-11-11 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | 孤独症诊断标志物MDSCs及其应用 |
CN115524490A (zh) * | 2022-10-24 | 2022-12-27 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | Hla-dr+cd14+cd56+单核细胞在aa或hlh中诊断的应用 |
Non-Patent Citations (3)
Title |
---|
RIIKKA TURUNEN: "Increased CD11b-density on circulating phagocytes as an early sign of late-onset sepsis in extremely low-birth-weight infants", PEDIATR RES., vol. 57, no. 2, 28 February 2005 (2005-02-28), pages 270 - 275, XP003007031, DOI: 10.1203/01.PDR.0000148717.59861.2C * |
彭林: "血小板活化在新生儿坏死性小肠结肠炎中的早期诊断价值", CNKI硕士电子期刊(天津医科大学), vol. 2009, no. 12, 31 December 2009 (2009-12-31) * |
王娟;彭林;: "血小板活化对新生儿坏死性小肠结肠炎诊断的临床意义", 临床荟萃, no. 06, 20 March 2009 (2009-03-20), pages 505 - 508 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6018923B2 (ja) | 敗血症の予後の予測方法 | |
Solders et al. | MAIT cells accumulate in placental intervillous space and display a highly cytotoxic phenotype upon bacterial stimulation | |
Hosseini et al. | A shift in the balance of T17 and Treg cells in menstrual blood of women with unexplained recurrent spontaneous abortion | |
Yang et al. | Increased serum IL-10 in lupus patients promotes apoptosis of T cell subsets via the caspase 8 pathway initiated by Fas signaling | |
CN115524490B (zh) | Hla-dr+cd14+cd56+单核细胞在aa或hlh中诊断的应用 | |
Jeon et al. | Positive maternal C-reactive protein predicts neonatal sepsis | |
KR102044940B1 (ko) | 파종성 혈관 내 응고 증후군 또는 감염성 파종성 혈관 내 응고 증후군을 검출하는 방법 | |
CN104160039A (zh) | 川崎病的生物标志物 | |
FR2809182A1 (fr) | Detection de l'il-6 pour la prevision des risques d'accouchement premature | |
Linssen et al. | Automation and validation of a rapid method to assess neutrophil and monocyte activation by routine fluorescence flow cytometry in vitro | |
Meganck et al. | Development of a method for isolating bovine colostrum mononuclear leukocytes for phenotyping and functional studies | |
Urschel et al. | C3d plasma levels and CD21 expressing B-cells in children after ABO-incompatible heart transplantation: Alterations associated with blood group tolerance | |
Liu et al. | The epidemiological and clinical characteristics of 2019 novel coronavirus infection in Changsha, China | |
CN117030580A (zh) | LDNs在坏死性小肠结肠炎诊断中的应用 | |
EP2743701B1 (en) | Method of diagnosing surgical site infections | |
Ahmed et al. | Comparison of complement activity in adult and preterm sheep serum | |
Alecsandru et al. | Ovarian stimulation does not influence the uterine immune environment in healthy infertile women | |
Garcia-Flores et al. | Deciphering maternal-fetal cross-talk in the human placenta during parturition using single-cell RNA sequencing | |
CN110082538B (zh) | CCR9+IL-17+Treg细胞在制备用于检测NEC的试剂盒中的应用 | |
Masoumi et al. | Serum Levels of Soluble Fas and Fas Ligand in Iranian Women with Pre-eclampsia | |
Saydullayevich et al. | Some Laboratory Indicators of Inflammatory Cytokines in Helicobacter Pylori-Associated Iron and Vitamin V12 Deficiency Anemia | |
Rescigno et al. | Role of the Maternal Gut Microbiota in Immune Activation at the Maternal-Fetal Interface Impact on Preeclampsia | |
CN109212178B (zh) | B淋巴细胞比例作为预测妊娠期糖尿病孕妇胰岛素抵抗水平的标志物及其应用 | |
Shangaris et al. | Single-cell transcriptomics reveals markers of regulatory T cell dysfunction in Gestational Diabetes Mellitus | |
Mihalic et al. | Gestational diabetes mellitus dysregulates the PD-1/PD-L1 axis at the feto-maternal interface |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |